InoCardia: Novel human-cell based assay for assessment of cardiovascular liability
Co-funded by Innovate UK, NC3Rs, MRC and EPSRC
When drugs/chemicals are developed to treat a particular disease or for human use purposes they sometimes have side effects that cause damage to the heart. Occasionally these dangerous side effects are only recognised after the drug/chemical has been marketed & taken/used by thousands of people.
This is a significant risk to human health & is costly to the pharmaceutical industry when a dangerous product is withdrawn from market. Although side effects of drugs can be caused by many things, one area of great concern is the effects of drugs on the force that heart muscle can produce during its role in pumping blood around the body.
Current drug testing relies on the use of animals such that often the tests do not do well in predicting the effect on humans. Development of a human heart-cell contractility assay would greatly improve the understanding of the human relevance of non-clinical findings; a chemical might cause a change in cardiac contractility in animals, but not humans & vice versa. We aim to develop a test that uses human heart cells in a way that can efficiently test many drugs/chemicals used in high-value industries & reduce the risk of causing any damage to the heart.
The development & commercialisation of a human cardiomyocyte contractility assay as a Service by InoCardia will bring benefits to a wide range of stakeholders:
To research organisations: 1. Reduced toxicology screening costs; 2. Reduced attrition rates; 3. reduced numbers of animals used; 4. reduced discovery costs overall; 5. scientists freed from repetitive screening activities will be redeployed into value creation exercises. Near term impact, 1-3 years. Longer term (10+years) reduced numbers of cardiovascular (CV) driven Adverse Drug Reactions drug withdrawals saving £Bn to the Pharmaceutical Development process.
The assay will: 1. support the safety testing of compounds that are uniquely active on the human target; 2. help define the human relevance of nonclinical findings; 3. improve success rates as reduced contractility liable drug candidates have an improved probability of clinical trials success; 4. increase rate of Development stage success; 5. decrease cost of Development; 6. Increase approval success rates, as well as reduced post approval withdrawal rates. Mid-long-term impact, 5-10 years.
To Biotechnological, Nutriceutical, Agrochemical & Cosmetic industries: Animal testing within these sectors is either banned (in relation to Cosmetics testing in UK & EU) or undesirable, yet product safety is required. Product labels featuring 'Not tested on animals' are desirable. Use of predictive human-based assays overcome the problem but few are available generally & none are available to detect inotropy. Customers need a low-cost but relevant means to test new products & provide human safety reassurance.
To patients: 1. Drugs with less contractility liability reach the market; 2. Drugs withdrawn from the market for unacceptable CV risk represent a significant human health issue. 3. higher dosing tolerated; 4. Higher efficacy of drugs & treatments. Long term impact, 10 years. To UK: Given the global nature of our customer base, this project will benefit Britain through: 1. increased exports; 2. creation of high-quality bioscience research jobs; 3. retention of high quality staff in the UK; 4. support of the global reputation of the UK to support an advanced science-based research industry; 5. Successful spin-outs, inspire other spin-outs; 6. Magnifying Britain's innovation commercialization base.
This Innovate UK/NC3R grant will support InoCardia to contribute to the growth of UK & EU R&D capacity & product development as well as gaining a competitive edge.
Identification of novel double-stranded RNA elements in developing antibiotic resistance in the agricultural environment
The goal of the project is to identify and subsequently characterise the dsRNA dimension of the animal gut microflora (both the differential presence of antisense bound to mRNA and phage dsRNAs containing novel genetic information in response to AB pressure). Identification of novel functional dsRNAs (asRNA bound to its target and phage dsRNAs involved in AR) will mark a paradigm shift in our understanding of the development of AR and future approaches to treating infections.